探讨CD₁₀₅单克隆抗体(monoclonal antibody, mAb)标记的微血管密度(microvascular density, MVD)在宫颈癌(cervical cancer)发生发展过程中的表达及其与临床病理指标的相关性研究。

选择2005年9月至2009年1月在广东省妇幼保健院手术切除的宫颈癌标本80例，将其按临床分期分为宫颈原位癌组(n＝30，0期)，宫颈早浸润癌组(n＝15，Ⅰ_A期)，宫颈浸润癌组(n＝35，Ⅰ_B～Ⅲ_B)；按恶性肿瘤的病理分级，将其分为Ⅰ级组(n＝5)，Ⅱ级组(n＝35)，Ⅲ级组(n＝10)；按浸润癌中淋巴结转移情况分为淋巴结呈阳性组(n＝8)，淋巴结呈阴性组(n＝42)。采用免疫组织化学SP法检测宫颈原位癌组、宫颈早浸润癌组和宫颈浸润癌组患者肿瘤间质中新生血管内皮标志物CD₁₀₅表达水平，同时观察用CD₁₀₅单克隆抗体标记的微血管密度，在肿瘤发展不同阶段的表达及与临床病理指标相关性。

用CD₁₀₅单克隆抗体标记肿瘤间质的微血管密，在宫颈原位癌组、宫颈早浸润癌组和宫颈浸润癌组比较，差异有显著意义(P<0.05)，在浸润癌中宫颈癌病理分级各组间微血管密度比较，差异无显著意义(P>0.05)；淋巴结呈阴性和阳性组间比较，差异有显著意义(P<0.05)；进一步行L-S-D检验显示，宫颈原位癌组与早浸润癌组比较，差异无显著意义(P＝0.528)。微血管密度分别在患者年龄及肿瘤直径间无相关性(r＝－0.200，P＝0.863；r＝0.353，P＝0.12)。

CD₁₀₅单克隆抗体标记的微血管密度与宫颈癌的临床分期及预后相关，可为宫颈原位癌和宫颈早浸润癌治疗提供理论依据。

To explore the relationship between microvascular density(MVD) marked by CD₁₀₅ monoclonal antibody (mAb) and stages of cervical cancer, clinical pathological factors.

From September 2005 to January 2009, cervical cancer specimens were stained by immunohistochemistry of CD₁₀₅ monoclonal antibody marked by microvascular density in 30 cases of carcinoma in situ(stage 0), 15 cases of early invasive cervical cancer (stage Ⅰ_A) and 35 cases of invasive cervical cancer (stage Ⅰ_B-Ⅱ_B). Furthermore, 50 cases with invasive cervical cancer were divided into group grade Ⅰ(n=5), group grade Ⅱ(n=35) and group grade Ⅲ (n=10) according to pathological grade of malignant tumor, and node-positive group (n=8) and node-negative group (n=42) according to lymph node metastasis. The expression of the vascular endothelial cell marked by CD₁₀₅ monoclonal antibody in tumor interstitium of carcinoma in situ, early invasive cervical cancer, and invasive cervical cancer were detected by immunohistochemical SP method. Meanwhile, the correlation between the expression of microvascular density marked by CD₁₀₅ monoclonal antibody in different stages of tumor development and clinicopathological factors was observed.

The microvascular density marked by CD₁₀₅ monoclonal antibody among carcinoma in situ(n=30, stage 0), early invasive cervical cancer (n=15, stage Ⅰ_A) and invasive cervical cancer (n=30, stage Ⅰ_B-Ⅱ_B) were significant difference(P<0.05). But with the further test of L-S-D, microvascular density had no significant difference between carcinoma in situ and early invasive cervical cancer (P=0.528). Microvessel density in lymph node positive group was higher than that of lymph node negative group(P=0.035), and among group grade Ⅰ, group grade Ⅱ and group grade Ⅲ had no significant difference (P=0.059).

Microvascular density marked by CD₁₀₅ is relative to clinical stages and prognosis of cervical cancer. It will give the therapy theory evidence of carcinoma in situ and early invasive cervical cancer.